Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients

Autores
Perroud, Herman Andrés; Rico, Maria Jose; Alasino, Carlos; Queralt, Fransisco; Mainetti, Leandro Ernesto; Pezzotto, Stella Maris; Rozados, Viviana Rosa; Scharovsky, Olga Graciela
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Metronomic chemotherapy (MCT), the chronic administration, at regular intervals, of low doses of chemotherapeutic drugs without extended rest periods, allows chronic treatment with therapeutic efficacy and low toxicity. Our preclinical results suggested that combined MCT with cyclophosphamide and celecoxib could inhibit breast cancer growth. The aim of this study was to determine the toxicity, safety and efficacy of oral MCT with cyclophosphamide 50 mg per orem daily and celecoxib 400 mg (200 mg per orem two-times a day) in advanced breast cancer patients. During the first stage of the study, the therapeutic response consisted of prolonged stable disease for ≥24 weeks in six out of 15 (40%) patients with a median duration of 37.5 weeks and a partial response in one out of 15 (response rate: 6.7%) patients lasting 6 weeks . The overall clinical benefit rate was 46.7%. The median time to progression was 14 weeks. Progression-free survival at 24 weeks was 40% and the 1-year overall survival rate was 46.7%. The adverse events were mild (gastric, grade 1; and hematologic, grade 1 or 2). No grade 3 or 4 toxicities were associated with the treatment. Evaluation of patients’ quality of life showed no changes during the response period. MCT with cyclophosphamide plus celecoxib is safe and shows a therapeutic effect in advanced breast cancer patients.
Fil: Perroud, Herman Andrés. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Rico, Maria Jose. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Alasino, Carlos. Instituto de Oncología de Rosario; Argentina
Fil: Queralt, Fransisco. Instituto de Oncología de Rosario; Argentina
Fil: Mainetti, Leandro Ernesto. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pezzotto, Stella Maris. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina
Fil: Rozados, Viviana Rosa. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina
Fil: Scharovsky, Olga Graciela. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
Breast Cancer
Metronomic Chemotherapy
Cyclophosphamide
Celecoxib
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/21817
Acceder
id CONICETDig_fab44b8056f2dc3b0e5d179620250894
oai_identifier_str oai:ri.conicet.gov.ar:11336/21817
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patientsPerroud, Herman AndrésRico, Maria JoseAlasino, CarlosQueralt, FransiscoMainetti, Leandro ErnestoPezzotto, Stella MarisRozados, Viviana RosaScharovsky, Olga GracielaBreast CancerMetronomic ChemotherapyCyclophosphamideCelecoxibhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Metronomic chemotherapy (MCT), the chronic administration, at regular intervals, of low doses of chemotherapeutic drugs without extended rest periods, allows chronic treatment with therapeutic efficacy and low toxicity. Our preclinical results suggested that combined MCT with cyclophosphamide and celecoxib could inhibit breast cancer growth. The aim of this study was to determine the toxicity, safety and efficacy of oral MCT with cyclophosphamide 50 mg per orem daily and celecoxib 400 mg (200 mg per orem two-times a day) in advanced breast cancer patients. During the first stage of the study, the therapeutic response consisted of prolonged stable disease for ≥24 weeks in six out of 15 (40%) patients with a median duration of 37.5 weeks and a partial response in one out of 15 (response rate: 6.7%) patients lasting 6 weeks . The overall clinical benefit rate was 46.7%. The median time to progression was 14 weeks. Progression-free survival at 24 weeks was 40% and the 1-year overall survival rate was 46.7%. The adverse events were mild (gastric, grade 1; and hematologic, grade 1 or 2). No grade 3 or 4 toxicities were associated with the treatment. Evaluation of patients’ quality of life showed no changes during the response period. MCT with cyclophosphamide plus celecoxib is safe and shows a therapeutic effect in advanced breast cancer patients.Fil: Perroud, Herman Andrés. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Rico, Maria Jose. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Alasino, Carlos. Instituto de Oncología de Rosario; ArgentinaFil: Queralt, Fransisco. Instituto de Oncología de Rosario; ArgentinaFil: Mainetti, Leandro Ernesto. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Pezzotto, Stella Maris. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; ArgentinaFil: Rozados, Viviana Rosa. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; ArgentinaFil: Scharovsky, Olga Graciela. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFuture Medicine2013-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/21817Perroud, Herman Andrés; Rico, Maria Jose; Alasino, Carlos; Queralt, Fransisco ; Mainetti, Leandro Ernesto; et al.; Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients; Future Medicine; Future Oncology; 9; 3; 3-2013; 451-4621479-6694CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.2217/fon.12.196info:eu-repo/semantics/altIdentifier/url/https://www.futuremedicine.com/doi/10.2217/fon.12.196info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:45:49Zoai:ri.conicet.gov.ar:11336/21817instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:45:49.226CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
title Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
spellingShingle Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
Perroud, Herman Andrés
Breast Cancer
Metronomic Chemotherapy
Cyclophosphamide
Celecoxib
title_short Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
title_full Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
title_fullStr Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
title_full_unstemmed Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
title_sort Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
dc.creator.none.fl_str_mv Perroud, Herman Andrés
Rico, Maria Jose
Alasino, Carlos
Queralt, Fransisco
Mainetti, Leandro Ernesto
Pezzotto, Stella Maris
Rozados, Viviana Rosa
Scharovsky, Olga Graciela
author Perroud, Herman Andrés
author_facet Perroud, Herman Andrés
Rico, Maria Jose
Alasino, Carlos
Queralt, Fransisco
Mainetti, Leandro Ernesto
Pezzotto, Stella Maris
Rozados, Viviana Rosa
Scharovsky, Olga Graciela
author_role author
author2 Rico, Maria Jose
Alasino, Carlos
Queralt, Fransisco
Mainetti, Leandro Ernesto
Pezzotto, Stella Maris
Rozados, Viviana Rosa
Scharovsky, Olga Graciela
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Breast Cancer
Metronomic Chemotherapy
Cyclophosphamide
Celecoxib
topic Breast Cancer
Metronomic Chemotherapy
Cyclophosphamide
Celecoxib
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Metronomic chemotherapy (MCT), the chronic administration, at regular intervals, of low doses of chemotherapeutic drugs without extended rest periods, allows chronic treatment with therapeutic efficacy and low toxicity. Our preclinical results suggested that combined MCT with cyclophosphamide and celecoxib could inhibit breast cancer growth. The aim of this study was to determine the toxicity, safety and efficacy of oral MCT with cyclophosphamide 50 mg per orem daily and celecoxib 400 mg (200 mg per orem two-times a day) in advanced breast cancer patients. During the first stage of the study, the therapeutic response consisted of prolonged stable disease for ≥24 weeks in six out of 15 (40%) patients with a median duration of 37.5 weeks and a partial response in one out of 15 (response rate: 6.7%) patients lasting 6 weeks . The overall clinical benefit rate was 46.7%. The median time to progression was 14 weeks. Progression-free survival at 24 weeks was 40% and the 1-year overall survival rate was 46.7%. The adverse events were mild (gastric, grade 1; and hematologic, grade 1 or 2). No grade 3 or 4 toxicities were associated with the treatment. Evaluation of patients’ quality of life showed no changes during the response period. MCT with cyclophosphamide plus celecoxib is safe and shows a therapeutic effect in advanced breast cancer patients.
Fil: Perroud, Herman Andrés. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Rico, Maria Jose. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Alasino, Carlos. Instituto de Oncología de Rosario; Argentina
Fil: Queralt, Fransisco. Instituto de Oncología de Rosario; Argentina
Fil: Mainetti, Leandro Ernesto. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pezzotto, Stella Maris. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina
Fil: Rozados, Viviana Rosa. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina
Fil: Scharovsky, Olga Graciela. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Metronomic chemotherapy (MCT), the chronic administration, at regular intervals, of low doses of chemotherapeutic drugs without extended rest periods, allows chronic treatment with therapeutic efficacy and low toxicity. Our preclinical results suggested that combined MCT with cyclophosphamide and celecoxib could inhibit breast cancer growth. The aim of this study was to determine the toxicity, safety and efficacy of oral MCT with cyclophosphamide 50 mg per orem daily and celecoxib 400 mg (200 mg per orem two-times a day) in advanced breast cancer patients. During the first stage of the study, the therapeutic response consisted of prolonged stable disease for ≥24 weeks in six out of 15 (40%) patients with a median duration of 37.5 weeks and a partial response in one out of 15 (response rate: 6.7%) patients lasting 6 weeks . The overall clinical benefit rate was 46.7%. The median time to progression was 14 weeks. Progression-free survival at 24 weeks was 40% and the 1-year overall survival rate was 46.7%. The adverse events were mild (gastric, grade 1; and hematologic, grade 1 or 2). No grade 3 or 4 toxicities were associated with the treatment. Evaluation of patients’ quality of life showed no changes during the response period. MCT with cyclophosphamide plus celecoxib is safe and shows a therapeutic effect in advanced breast cancer patients.
publishDate 2013
dc.date.none.fl_str_mv 2013-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/21817
Perroud, Herman Andrés; Rico, Maria Jose; Alasino, Carlos; Queralt, Fransisco ; Mainetti, Leandro Ernesto; et al.; Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients; Future Medicine; Future Oncology; 9; 3; 3-2013; 451-462
1479-6694
CONICET Digital
CONICET
url http://hdl.handle.net/11336/21817
identifier_str_mv Perroud, Herman Andrés; Rico, Maria Jose; Alasino, Carlos; Queralt, Fransisco ; Mainetti, Leandro Ernesto; et al.; Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients; Future Medicine; Future Oncology; 9; 3; 3-2013; 451-462
1479-6694
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.2217/fon.12.196
info:eu-repo/semantics/altIdentifier/url/https://www.futuremedicine.com/doi/10.2217/fon.12.196
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Future Medicine
publisher.none.fl_str_mv Future Medicine
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268755511476224
score 13.13397

Publicaciones similares